Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ: HRMY · IEX Real-Time Price · USD
29.03
-0.28 (-0.96%)
May 17, 2024, 4:00 PM EDT - Market closed
HRMY Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for HRMY stock have an average target of 44, with a low estimate of 27 and a high estimate of 69. The average target predicts an increase of 51.57% from the current stock price of 29.03.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HRMY stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $50 → $52 | Strong Buy | Maintains | $50 → $52 | +79.13% | May 1, 2024 |
| Needham | Needham | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +72.24% | Apr 30, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $49 | Buy | Reiterates | $49 | +68.79% | Apr 12, 2024 |
| Needham | Needham | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +72.24% | Apr 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +72.24% | Apr 9, 2024 |
Financial Forecast
Revenue This Year
726.03M
from 582.02M
Increased by 24.74%
Revenue Next Year
857.44M
from 726.03M
Increased by 18.10%
EPS This Year
2.97
from 2.13
Increased by 39.28%
EPS Next Year
4.10
from 2.97
Increased by 38.11%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 755.2M | 934.3M | 1.2B | 1.6B | 2.4B |
| Avg | 726.0M | 857.4M | 1.0B | 1.2B | 1.5B |
| Low | 686.4M | 773.0M | 829.8M | 980.2M | 759.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 29.7% | 28.7% | 36.8% | 55.5% | 97.8% |
| Avg | 24.7% | 18.1% | 16.9% | 19.8% | 23.6% |
| Low | 17.9% | 6.5% | -3.2% | -2.2% | -36.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.62 | 5.17 | 6.84 | 10.43 | 5.83 |
| Avg | 2.97 | 4.10 | 5.19 | 9.00 | 5.66 |
| Low | 2.40 | 3.28 | 4.14 | 7.56 | 5.44 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 70.1% | 74.1% | 66.8% | 100.8% | -35.2% |
| Avg | 39.3% | 38.1% | 26.7% | 73.2% | -37.1% |
| Low | 12.7% | 10.7% | 0.9% | 45.5% | -39.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.